TGFB1 and myeloid sarcoma: In a previous study on MS patients [22] we found that the “down- or up-regulation” of sCD30 levels, respectively linked to the “up- or down-regulation” of TGFβ levels, within physiological or pathological ranges, are dual biomarker for homeostasis or imbalance in immunological and neurological pathways and success or failure of IFNβ therapeutic treatment.